🔴 Vera Therapeutics is trading 4.1% down today on profit-taking after its recent FDA-driven rally

Vera Therapeutics is trading 4.1% down at $40.76 as the stock undergoes consolidation following a significant rally earlier in July.

• The stock's recent surge was fueled by the FDA's accelerated approval of TRUTAKNA for the treatment of IgA nephropathy.
• With no fresh company-specific news today, the decline appears to be a result of investors locking in gains following the post-approval run-up and subsequent analyst optimism.